From one entrepreneur
to another
Excelerate Health was started by entrepreneurs for entrepreneurs. We focus exclusively on Pharma Tech. We have deep operational experience. We have assembled a network of pharma, provider, payer, and strategic partners, many of whom may become your customers.
Our Investment Criteria
Send your pitch to info@ExcelerateHealth.com
A partner reviews every pitch. To help us evaluate quickly, please include:
- 01Founder & companyYour name, role, company name, and website.
- 02Stage & roundPre-seed / Seed / Series A, target raise, lead status, and timing.
- 03What you’re buildingOne paragraph on the problem, your wedge, and why now.
- 04TractionRevenue, pilots, pipeline, usage, retention, customer feedback, or other evidence of market pull.
- 05Pitch deckAttach a PDF or PPT.
Hands-on company building from inception through sale
Customer access
Many of our investors and advisors are your potential customers, opening doors that take other founders quarters.
Operating muscle
Hiring, GTM, governance, financing process, M&A, we’ve done it. We sit in board seats and we sit in the room.
Healthcare-only network
Strategic partners and contract resources from across the healthcare community to accelerate adoption and revenue.
From pitch to decision in 30–60 days
Questions founders ask before pitching
We are a specialist fund focused on AI-powered Pharma SaaS tech and services. Our partners bring deep operator experience building and scaling Pharma Tech and life-science services companies, and we don't just write checks. We partner operationally and co-build with founders.
EHV invests in B2B SaaS Pharma Tech and tech-enabled Pharma services companies. We look for capital-efficient companies where we can add significant value and exit within a reasonable amount of time.
We typically lead or co-lead late seed or early Series A start-ups, with initial checks of roughly $500K to $2M and follow-on capital reserved, but remain opportunistic if we can add value elsewhere. We are generally part of the first professional money in the company, and we take an active role in syndicating our deals with our investment partners to bring in additional capital and value.
EHV invests in passionate management teams that don't have all the answers, a team that's willing to be mentored and advised by experienced entrepreneurs to accelerate the growth of their company. We are focused only on Pharma SaaS and tech-enabled Pharma services with a B2B model.
Yes, a thoughtful pitch deck and financial plan are very helpful. We prefer detailed cash forecasts for the next 18-24 months, with an eye toward capital efficiency, scalable margins, and a clear path to pharma buyer adoption or commercialization. Highlight key inflection points, data infrastructure, and defensibility.
We look for clarity on the pain point you address in pharma or life sciences, how AI/data/tech enables a defensible moat, market size, capital efficiency and margins, a credible commercialization or exit pathway, and a transparent use-of-capital plan with clear milestones and runway. If your deck addresses those items concisely, you will catch our attention.
Assuming the company has everything in order, in electronic format, it takes around 30-60 days. If this is your first time through diligence, search "VC investment due diligence checklist." The sooner you start organizing materials, the better, you will eventually need all of them, especially as you prepare for an exit.
Our decision-making process follows a venture capital model: the managing partners, with feedback from the advisory board and broader network, make the final investment decision. We have an agile process for looking at deals, and once we make a decision to invest, the investment is made directly from our committed funds.
Hands-on operational partnership: help with pharma commercialization, customer introductions, pricing architecture, early go-to-market planning, recruiting, interim leadership if needed, and strategic advisor network access. We also provide follow-on capital and leverage our deep relationships in pharma and life sciences to accelerate adoption, scale your business, and pave a path toward a strong exit.